1 week Ago By Defense World Staff
Arrowstreet Capital Limited Partnership trimmed its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 92.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 158,457 shares of the biopharmaceutical company’s stock after selling 1,872,718 shares during the period.
Arrowstreet Capital Limited Partnership’s holdings in Bristol-Myers Squibb were worth $8,962,000 as of its most recent SEC filing. Other hedge funds also recently modified their holdings of the company. MV Capital Management Inc.
boosted its holdings in Bristol-Myers Squibb by 16.9% in the fourth quarter. MV Capital Management Inc.
now owns 3,155 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 456 shares in the last quarter. Allianz SE acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at about $5,679,000. Tucker Asset Management LLC raised its stake in shares of Bristol-Myers Squibb by 3,313.
6% in the 4th quarter. Tucker Asset Management LLC now owns 4,779 shares of the biopharmaceutical company’s stock valued at $270,000 after acquiring an additional 4,639 shares in the last quarter. Intrust Bank NA lifted its holdings in Bristol-Myers Squibb by 38.
8% in the 4th quarter. Intrust Bank NA now owns 31,791 shares of the biopharmaceutical company’s stock worth $1,798,000 after purchasing an additional 8,894 shares during the last quarter. Finally, Biondo Investment Advisors LLC boosted its position in Bristol-Myers Squibb by 0.
9% during the fourth quarter. Biondo Investment Advisors LLC now owns 142,200 shares of the biopharmaceutical company’s stock worth $8,043,000 after purchasing an additional 1,260 shares during the period. Institutional investors and hedge funds own 76.
41% of the company’s stock. Insider Buying and Selling at Bristol-Myers SquibbIn other news, EVP Samit Hirawat bought 1,823 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was bought at an average price of $54.
84 per share, for a total transaction of $99,973.32. Following the completion of the purchase, the executive vice president now owns 63,932 shares of the company’s stock, valued at approximately $3,506,030.
88. The trade was a 2.94 % increase in their position.
The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.09% of the company’s stock.
Wall Street Analysts Forecast GrowthA number of brokerages have recently weighed in on BMY. Jefferies Financial Group upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $63.00 to $70.
00 in a research note on Monday, December 16th. Bank of America reissued a “neutral” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th.
Truist Financial raised their price target on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th.
Wells Fargo & Company boosted their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research report on Friday, February 7th.
Finally, Cantor Fitzgerald raised their target price on Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th.
Two research analysts have rated the stock with a sell rating, ten have given a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus target price of $57.
86.Get Our Latest Stock Analysis on Bristol-Myers SquibbBristol-Myers Squibb Stock PerformanceNYSE:BMY opened at $55.32 on Monday.
The firm has a market capitalization of $112.56 billion, a PE ratio of -12.52, a price-to-earnings-growth ratio of 2.
07 and a beta of 0.41. The company has a quick ratio of 1.
15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90.
Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33.
The firm has a 50-day moving average price of $58.62 and a 200 day moving average price of $56.68.
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.
47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.
93% and a negative net margin of 18.53%. Research analysts anticipate that Bristol-Myers Squibb will post 6.
74 earnings per share for the current fiscal year. Bristol-Myers Squibb Dividend AnnouncementThe company also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be issued a dividend of $0.
62 per share. This represents a $2.48 annualized dividend and a yield of 4.
48%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is currently -56.
11%. Bristol-Myers Squibb Profile (Free Report)Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases.
The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.Further ReadingFive stocks we like better than Bristol-Myers SquibbHow to Invest in Small Cap Stocks Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?ESG Stocks, What Investors Should KnowDisney 2025 Shareholders: Major Updates for InvestorsWhat is MarketRankTM? How to Use itAdvance Auto Parts Stock: A Classic Rebound Play in the Making.
